
Innovent Biologics announces that the NDA for mazdutide, a GLP-1R/GCGR dual agonist for chronic weight management in adults with obesity or overweight, has been accepted by China's NMPA. Mazdutide, the first of its kind, completed Phase 3 trials successfully. Results showed superiority over placebo in weight reduction and cardiometabolic endpoints. The safety profile remained consistent with previous studies. Detailed results from the GLORY-1 trial will be disclosed in medical conferences or journals later in 2024.
Like
Save
Share